[肝素诱导的II型血小板减少症(HIT II):肝素用于预防血栓栓塞的致命并发症]。

IF 0.6 4区 医学 Q4 EMERGENCY MEDICINE
Unfallchirurgie Pub Date : 1996-12-01
G Hobbensiefken, B Driller, V Studtmann, K Kunz, G Lehrbach
{"title":"[肝素诱导的II型血小板减少症(HIT II):肝素用于预防血栓栓塞的致命并发症]。","authors":"G Hobbensiefken,&nbsp;B Driller,&nbsp;V Studtmann,&nbsp;K Kunz,&nbsp;G Lehrbach","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Heparin-induced thrombocytopenia type II (HIT II) is the most severe complication during prophylactic treatment with low doses of heparin. Five cases demonstrate the life-threatening consequences of this immune-mediated thromboembolic disease. In order to improve prognosis it is most important to start therapy just before diagnosis is assured by laboratory tests. First choice treatment is the low-molecular-weight heparinoid Orgaran. In patients with an episode of HIT II both low-molecular-weight heparin and unfractionated heparin will be contraindicated for a life time.</p>","PeriodicalId":29789,"journal":{"name":"Unfallchirurgie","volume":"22 6","pages":"248-52"},"PeriodicalIF":0.6000,"publicationDate":"1996-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Heparin-induced thrombocytopenia Type II (HIT II) A fatal complication of heparin use for thromboembolism prevention].\",\"authors\":\"G Hobbensiefken,&nbsp;B Driller,&nbsp;V Studtmann,&nbsp;K Kunz,&nbsp;G Lehrbach\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Heparin-induced thrombocytopenia type II (HIT II) is the most severe complication during prophylactic treatment with low doses of heparin. Five cases demonstrate the life-threatening consequences of this immune-mediated thromboembolic disease. In order to improve prognosis it is most important to start therapy just before diagnosis is assured by laboratory tests. First choice treatment is the low-molecular-weight heparinoid Orgaran. In patients with an episode of HIT II both low-molecular-weight heparin and unfractionated heparin will be contraindicated for a life time.</p>\",\"PeriodicalId\":29789,\"journal\":{\"name\":\"Unfallchirurgie\",\"volume\":\"22 6\",\"pages\":\"248-52\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"1996-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Unfallchirurgie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"EMERGENCY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Unfallchirurgie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

肝素诱导的II型血小板减少症(HIT II)是低剂量肝素预防性治疗中最严重的并发症。五个病例证明了这种免疫介导的血栓栓塞性疾病的危及生命的后果。为了改善预后,最重要的是在实验室检查确定诊断之前开始治疗。首选的治疗方法是低分子类肝素器官。在HIT II发作的患者中,低分子肝素和未分离肝素终身禁忌症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Heparin-induced thrombocytopenia Type II (HIT II) A fatal complication of heparin use for thromboembolism prevention].

Heparin-induced thrombocytopenia type II (HIT II) is the most severe complication during prophylactic treatment with low doses of heparin. Five cases demonstrate the life-threatening consequences of this immune-mediated thromboembolic disease. In order to improve prognosis it is most important to start therapy just before diagnosis is assured by laboratory tests. First choice treatment is the low-molecular-weight heparinoid Orgaran. In patients with an episode of HIT II both low-molecular-weight heparin and unfractionated heparin will be contraindicated for a life time.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.40
自引率
25.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信